Accrued Expenses and Other Current Liabilities

3 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

(in thousands)	MARCH 31, 2018		DECEMBER 31, 2017
Accrued compensation and benefits (1)	$	4,246	$	7,886
Accrued consulting and professional fees	2,788		3,841
Accrued research and development expenses (2)	1,361		1,855
Accrued other (3)	10,675		5,357
Total accrued expenses and other current liabilities	$	19,070	$	18,939

(1) The decrease in accrued compensation and benefits primarily relates to the payment of 2017 annual incentives during the three months ended March 31, 2018.

(2) Comprised of accruals such as fees for investigative sites, contract research organizations, contract manufacturing organizations and other service providers that assist in conducting preclinical research studies and clinical trials.

(3) Comprised of accruals related to commercial manufacturing activities, interest payable and other business-related expenses. The increase at March 31, 2018 as compared to December 31, 2017 is due to a $5.8 million increase in accrued property, plant and equipment purchases as of March 31, 2018, primarily related to the Company’s manufacturing plant build-out in Ireland.